Viscosupplementation Market Share Business Strategies To 2030
According to the Market Statsville Group (MSG), the global viscosupplementation market size is expected to grow from USD 34,986.46 million in 2022 to USD 55,010.42 million by 2033, at a CAGR of 4.2% from 2023 to 2033.
The rise in the prevalence of osteoarthritis worldwide is a major factor boosting the growth of the global viscosupplementation market. The increase in the geriatric population and high prevalence of obesity is projected to contribute to the rise in the prevalence of OA, placing a significant burden on individuals, health systems, and social care systems worldwide. According to the Arthritis Foundation, 130 million individuals across the globe are likely to be affected by osteoarthritis by 2050. Minimally invasive surgeries minimize blood loss, reduce hospital stays, offer quicker rehabilitation, and have smaller incisions. Viscosupplement therapy exhibits a nearly 86% success rate in alleviating osteoarthritis-related pain. The Asia-Pacific market is expected to experience substantial growth during the projected period, primarily due to the rising healthcare spending in the region. Furthermore, the relatively low manufacturing costs in countries like China and India have led to an increase in the number of production facilities, making the region attractive to global pharmaceutical and biotechnology companies.
Request Sample Copy of this Report: https://www.marketstatsville.com/buy-now/cbd-gummies-market?opt=3338&utm_source=free&utm_medium=harsh
Scope of the Global Viscosupplementation Market
The study categorizes the viscosupplementation market based on product type and end-users area at the regional and global levels.
By Product Type Outlook (Sales, USD Million, 2019-2033)
- Single Injection
- Three Injection
- Five Injection
By End-Users Outlook (Sales, USD Million, 2019-2033)
- Hospitals
- Orthopaedic Clinics/ASCs
By Region Outlook (Sales, USD Million, 2019-2033)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Italy
- France
- UK
- Spain
- Poland
- Russia
- The Netherlands
- Norway
- Czech Republic
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Malaysia
- Thailand
- Singapore
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Northern Africa
- Rest of MEA
Direct Purchase Report: https://www.marketstatsville.com/buy-now/viscosupplementation-market?opt=3338&utm_source=free&utm_medium=harsh
Three Injection segment accounts for the largest market share by product type
Based on the product type, the market is divided into single injection, three injection, and five injection. The three injection segment accounted for the global viscosupplementation market’s largest market share of around 44.3% in 2022, due to it has been shown to be effective in reducing joint pain and improving mobility in patients with osteoarthritis. Clinical studies have demonstrated that pain relief can be minimized by using three hyaluronic acid injections and will further improve joint function in patients with knee osteoarthritis. In addition, the three injection product type segment is often covered by insurance, which makes it more accessible to patients who may not be able to afford other treatment options.
Asia Pacific accounted for the largest market share by Region
Based on the regions, the global viscosupplementation market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. Asia Pacific accounted for the largest market share of around 42.2% in 2022, owing to the region’s large and growing aging population. As people age, the risk of joint pain and osteoarthritis increases, which is driving demand for viscosupplementation in the region. Further, the increasing prevalence of sports-related injuries also drives growth in the viscosupplementation market in Asia Pacific. As more people in the region participate in sports and physical activity, the risk of joint injuries also increases, which is creating a demand for treatments such as viscosupplementation. The growth of the viscosupplementation market in the Asia Pacific is the increasing availability and accessibility of healthcare services. As more people in the region gain access to healthcare, they are more likely to seek treatment for joint pain and osteoarthritis, driving demand for viscosupplementation.
Competitive Landscape: Global Viscosupplementation Market
The viscosupplementation market is a significant competitor, and extremely cutthroat in the sector is using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Major key players in the global viscosupplementation market are:
- Sanofi
- Anika Therapeutics, Inc.
- Seikagaku Corporation
- Zimmer Biomet
- Smith & Nephew Plc
- LG Chem
- Lifecore
- Ferring B.V.
- Fidia Farmaceutici S.p.A.
- Company 10
Request For Report Discount: https://www.marketstatsville.com/table-of-content/viscosupplementation-market
Global Viscosupplementation Market Dynamics
Drivers: Surging geriatric populations and the prevalence of osteoarthritis will drive the growth of the market
Osteoarthritis (OA) is a chronic and progressive condition where the cartilage in joints degenerates over time. This can lead to bone-to-bone contact, causing pain, stiffness, and difficulty in movement. OA commonly affects joints such as knees, hands, feet, spine, and also, though less frequently, the shoulder and hip joints. Although aging is a significant risk factor for OA, it is also linked to other factors that can be controlled or not, such as obesity, lack of physical activity, genetic predisposition, bone density, occupational injury, trauma, and gender. Osteoarthritis is caused due to inflammation, breakdown, and eventual degeneration of synovial fluid. Hyaluronan occurs naturally in synovial fluid and helps lubricate the joints. Thus, a hyaluronic acid-based injection restores some hyaluronan in the joints.